Amanta Healthcare Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹607 Cr

SteriPort Line 3 expected to contribute around INR120 crores annualized revenue, fully realized within 12 months post-commissioning (from August 2026). SteriPort Line 3 commissioning expected by August 2026, with annualized peak revenue of INR110-120 crores achievable within 12 months of commissioning.

From Amanta Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

📊 Revenue & Sales Performance

Rank 3

→SteriPort Line 3 expected to contribute around INR120 crores annualized revenue, fully realized within 12 months post-commissioning (from August 2026).
→SteriPort projected to generate roughly INR70 crores in top line during the 7 months remaining in FY27 and about INR425 crores revenue at peak utilization in FY28 including SVP.
→SVP facility to commence operations by March 2027, expected to drive growth in export-focused products like inhalation, ophthalmics, and preservative-free unit doses.
→SVP export revenues anticipated to comprise 60%-70% from advanced regulated markets (UK, Ireland, EU, Australia, Canada).
→Future growth drivers for FY27-FY29: inhalation products, ophthalmics, diluents in advanced markets.
→Focus on expanding sterile dosage forms, including exploring other packaging materials and drug delivery mechanisms beyond plastic.
→Capacity expansions and formulation development pipeline (20 products) expected to support sustained growth over next 2-3 years.
→Interest expense expected to reduce by FY28 indicating easing capex cycle.

📈 Profitability & Margins

Rank 3

→SteriPort Line 3 commissioning expected by August 2026, with annualized peak revenue of INR110-120 crores achievable within 12 months of commissioning.
→SVP facility to commence operations by March 2027, expanding presence in high-margin export markets (inhalation solutions, ophthalmics, preservative-free unit doses).
→Combined full capacity (SteriPort + SVP + existing) expected to generate peak revenue of around INR425 crores in FY28 with EBITDA around INR116 crores.
→Incremental ROCE on SteriPort Line 3 estimated at 16%-17%; SVP ROCE expected around 14%-15%.
→Operating leverage to improve with scaling, supported by captive solar power reducing power costs significantly (INR9 crores cost savings).
→EBITDA margins expected to remain stable around 25%-26% for FY27 and FY28.
→Interest expense expected to reduce after peak capex cycle; INR18-19 crores annualized interest expected in FY28.
→Growth drivers include new product pipeline with ~20 products under development, including inhalation and ophthalmics targeting advanced markets.

See what Amanta Healthcare Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

Yes

→SteriPort Line 3: Total capex of INR 90 crores; approx. INR 80 crores spent so far; commissioning expected by August 24-25, 2026.
→SVP Expansion: Total capex of INR 30 crores; about INR 7 crores spent so far; expected to be operational by March 2027.
→No immediate further capex planned for SteriPort beyond Line 3, despite demand-supply mismatch.
→Future exploration of other drug delivery mechanisms and packaging materials (e.g., glass) beyond current plastic packaging, with clarity expected by December 2026 or January 2027.
→Investment in formulation development team and new center under construction, intending 8-10 scientists and 3-4 regulatory affairs personnel for advanced markets.
→Solar power captive project capex contributing to slight interest expense increase; reduces monthly operational costs by approx. INR 75 lakh.
→Post-2027, focus will be on activity-centric investments to support existing capacity rather than large capex.

💰 Fundraising & Capital Structure

No information

→No explicit mention of any new fundraising through debt or equity in the provided transcript.
→Existing debt is being managed and expected to reduce annually by INR30-35 crores.
→Additional debt was taken for the solar captive power project but it is a strategic cost-saving move.
→Interest expenses are expected to reduce going forward as debt decreases.
→Current and near-term capex (SteriPort Line 3, SVP, solar) is mostly funded, with INR80 crores spent on SteriPort Line 3 and part of INR30 crores on SVP already spent.
→No discussion of fresh equity or debt issuance planned beyond current operational and capex financing.

See what Amanta Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

No information

The transcript provided does not explicitly mention the current or expected order book or pending orders for Amanta Healthcare Limited. However, some relevant insights include: - There is strong demand for SteriPort products, leading to an expansion in capacity from 6.6 crore to approximately 12 crore bottles per year. - SteriPort Line 3 commissioning is expected around August 24-25, 2026, with annualized revenue expected at INR 120 crores. - SVP facility is expected to be operational by March 2027, targeting advanced regulated markets with 60%-70% of SVP revenue expected from these markets. - The company is leveraging increasing demand with near-full utilization of existing capacities. - No direct comments on the size or value of the order book or pending orders were disclosed in the available transcript.

Key Metrics

1 of 5 growth signals positive in the Q1 FY27 call.

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

No information

How does Amanta Healthcare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Amanta Healthcare Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Price

₹195

Market Cap

₹607 Cr

P/E Ratio

39.6

Amanta Healthcare Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹6 Cr.

Full financials →

What Amanta Healthcar's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Amanta Healthcare Ltd Q1 FY27 results?

What is Amanta Healthcare Ltd share price analysis?

Amanta Healthcare Ltd currently shows a below-average growth signal. The stock trades at a P/E of 39.6 with a market cap of ₹607 Cr. Investors should review the full earnings analysis for detailed insights.

Is Amanta Healthcare Ltd planning capital expenditure?

SteriPort Line 3: Total capex of INR 90 crores; approx.

Keep Amanta Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

📊 Revenue & Sales Performance

🏗️ Capital Expenditure Plans

📋 Order Book & Pipeline

Key Metrics

Amanta Healthcare Ltd — Quarterly revenue & net profit

Continue your research

What Amanta Healthcar's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Frequently Asked Questions